| Similar Articles |
|---|
 |
The Motley Fool
December 28, 2005
Michael D. Leibert |
Like the Funds? Love the Advisor! Investors in T. Rowe Price funds do well, but investors in the advisor do even better.   |
The Motley Fool
August 10, 2010
Andrew Bond |
T. Rowe Price: Strengths, Weaknesses, Opportunities, Threats A look inside the business of T. Rowe Price. |
The Motley Fool
October 5, 2010
Brian Orelli |
You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure. |
The Motley Fool
July 20, 2009
Brian Orelli |
Overnight Triple! Yee-Haw! The joys of owning biotech companies. The latest beneficiary, Human Genome Sciences, is up more than 220% today because Benlysta, their new drug for lupus, works. |
The Motley Fool
September 30, 2010
Tim Hanson |
Today's Buy Opportunity: T. Rowe Price Group Why the Fool's buying shares of T. Rowe Price. |
The Motley Fool
November 17, 2010
Brian Orelli |
52 Years Down, 1 Month to Go Lupus treatment Benlysta moves closer to approval. |
The Motley Fool
June 14, 2010
Brian Orelli |
No Approval? No Problem! Investors shrug off Human Genome's news about its hepatitis C drug Zalbin. |
The Motley Fool
April 14, 2011
Brian Orelli |
Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year. |
The Motley Fool
October 26, 2004
Roger Nusbaum |
T. Rowe Price Has Wind in Its Sails Can the mutual fund firm do well in a bad environment for financial services? |
The Motley Fool
January 30, 2006
Stephen D. Simpson |
A Stock for Fund Fans While there's no doubt that T. Rowe Price runs a stable of high-quality funds, certain aspects of this company might trouble some investors. While not quite a buy, it's certainly not a sell, either. |
The Motley Fool
December 1, 2011
Dan Caplinger |
Has T. Rowe Price Become the Perfect Stock? T. Rowe Price has done almost everything it needs in order to reach our top score, and if its revenue growth continues, it could get there in the near future. |
The Motley Fool
December 6, 2010
Brian Orelli |
3-Month Delay? No Problem! Investors shrug off HGS' Benlysta delay. The Food and Drug Administration's delaying its decision on whether to approve Human Genome Sciences and GlaxoSmithKline's Benlysta shouldn't come as much of a surprise. |
The Motley Fool
October 26, 2011
Brian Orelli |
Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. |
The Motley Fool
July 22, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Baird turns bullish on Human Genome Sciences. |
The Motley Fool
October 24, 2007
Matt Koppenheffer |
Tallying T. Rowe's Earnings Investors, T. Rowe Price announced solid third-quarter results. |
The Motley Fool
February 27, 2009
Brian Orelli |
Waiting to Inhale Human Genome Sciences is guiding for revenue of $250 million this year compared to less than $50 million last year, thanks to its sale of anthrax emergency treatment ABthrax to the government. |
The Motley Fool
January 29, 2009
Rick Aristotle Munarriz |
Buy Mutual Funds, Sell Mutual Fund Stocks Naturally, the fourth quarter wasn't a good one for most fund operators. Now, T. Rowe Price has fallen like the rest of them. |
The Motley Fool
October 28, 2009
Rich Smith |
You're Wrong to Kick Sand at Under Armour In contrast to last quarter, when Under Armour leaned on its apparel segment for growth, this time footwear led the charge, and sales there spiked 150% year over year. |
The Motley Fool
July 28, 2005
Mike Cianciolo |
T. Rowe Rows Its Boat The mutual fund giant continues to increase its customer base and profits. |
The Motley Fool
December 22, 2009
Brian Orelli |
2009 Biotech Cheers and Jeers Lessons from biotech's 2009 surprises. Will 2010 be just as exciting? Considering that it's biotech, I'd have to say "yes." |
The Motley Fool
June 12, 2009
Brian Orelli |
Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side. |
The Motley Fool
September 27, 2007
Amanda B. Kish |
The Best Funds From T. Rowe Price: Part 1 A closer look at these T. Rowe Price funds: T. Rowe Price Personal Growth Fund... T. Rowe Price Spectrum Growth Fund... |
The Motley Fool
November 2, 2009
Brian Orelli |
Finally Convinced? Benlysta Works! Human Genome Sciences succeeds where others have failed. |
The Motley Fool
March 17, 2011
Brian Orelli |
Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping. |
The Motley Fool
July 27, 2010
Rich Smith |
What's Up With Under Armour? Sales, and profits -- everything but the stock price. |
The Motley Fool
October 5, 2005
Stephen D. Simpson |
Lupus Trials Spook Investors Lupus is a high-risk, high-reward indication, and today's disappointing trial results aren't the end of the story for Human Genome Sciences. Aggressive and experienced investors might want to take a look at this one, but this is clearly not a stock for the faint of heart. |
The Motley Fool
March 8, 2010
Amanda B. Kish |
Must-Read Mutual Fund News The latest from the fund industry: Fidelity makes some changes... Hidden risks of bond ETFs... T. Rowe Price and Oppenheimer Funds take the cake... |
The Motley Fool
January 29, 2008
Matt Koppenheffer |
Over the Top With T. Rowe Price The fund family's solid fourth-quarter earnings reflected its funds' strong performance during a tough time in the market. |
The Motley Fool
October 27, 2011
Amanda B. Kish |
Why T. Rowe Price Still Hits the Mark Don't let a down quarter scare you away from these funds. |
The Motley Fool
October 26, 2009
Rick Aristotle Munarriz |
3 Stocks That Blew the Market Away These stocks beat analyst expectations: Amazon.com... T. Rowe Price... Yahoo!... |
Chemistry World
March 15, 2011
Sarah Houlton |
Benlysta breaks 50 year Lupus drug drought The first new treatment for lupus erythematosus in half a century has been approved by the US Food and Drug Administration |
The Motley Fool
July 30, 2007
S.J. Caplan |
No Trouble for T. Rowe The investment company's second-quarter earnings show its strength to investors. |
The Motley Fool
June 12, 2007
Amanda B. Kish |
What Have You Done for Me Tomorrow? Upcoming leadership changes at the T. Rowe Price Growth Stock fund might make selling the best option. |
The Motley Fool
October 12, 2011
Robert Eberhard |
You Can't Judge a Brand by Its Uniforms Under Armour is more than just questionable college football uniforms. |
The Motley Fool
December 17, 2007
Rick Aristotle Munarriz |
4 Stocks That Took a Hike These companies recently raised their dividends: General Electric... T. Rowe Price... State Street...AT&T... |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
October 30, 2009
Brian Orelli |
Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening. |
The Motley Fool
April 18, 2011
Rick Aristotle Munarriz |
How to Invest in Groupon, Twitter, and Facebook Now A mutual fund offers an early pass into Web 2.0 darlings. |
The Motley Fool
April 27, 2004
Nathan Slaughter |
T. Rowe Price Impresses The no-load fund complex doubles earnings and attracts record inflows. |
BusinessWeek
April 30, 2007
Stanley Holmes |
Under Armour May Be Overstretched Why Under Armour is one of the biggest shorts on the Street. |
The Motley Fool
October 26, 2011
Robert Eberhard |
This Clothing Retail Stock Just Beat Expectations Under Armour grows revenue by 40% for the second quarter in a row. |
The Motley Fool
April 1, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Jesup and Collins are just a couple of fools in love ... with Human Genome Sciences. |
The Motley Fool
November 12, 2010
Brian Orelli |
Benlysta: Not Perfect, but Good Enough Human Genome should get past the FDA advisory panel next week. |
The Motley Fool
December 18, 2006
Rick Aristotle Munarriz |
4 Stocks That Took a Hike Companies with growing yields can make you rich in more ways than the obvious: WD-40... T. Rowe Price... General Electric... Steelcase... |
The Motley Fool
January 4, 2010
Rick Aristotle Munarriz |
Sizing Up Mutual Fund Predictions for 2009 After suffering through the double whammy of falling stock prices and investor redemptions in 2008, folks had little problem snapping up mutual fund shares once the equity markets began rallying in March. |
The Motley Fool
September 27, 2007
Amanda B. Kish |
The Best Funds From T. Rowe Price: Part 2 A closer look at these T. Rowe Price funds: T. Rowe Price Blue Chip Growth Fund... T. Rowe Price Summit Municipal Income Fund... |
The Motley Fool
December 30, 2011
Brian Orelli |
A Bad Year for the 6,300% Miracle Human Genome Sciences falls from grace. |
The Motley Fool
April 29, 2005
Mike Cianciolo |
T. Rowe Price Charges Ahead The mutual fund giant performs fairly well in a difficult market thanks to its loyal investors. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Lupus: How Big will Benlysta Become? Human Genome Sciences/GSK's Benlysta (belimumab) was approved by an FDA advisory committee in November -- to the cheers of many patients who had testified to their need of the novel therapy. |
The Motley Fool
September 21, 2007
Selena Maranjian |
A Fund That Hasn't Lost Money T. Rowe Price's Capital Appreciation fund invests in stocks, bonds, and cash, has low fees, and a 16-year winning streak. |
